Small caps round-up: Scancell, Software Radio, Aeorema

Scancell Holdings, a developer of therapeutic cancer vaccines, has announced that its protein ImmunoBody vaccine patent has been approved in the US. The patent, which has already been approved in Europe and Australia, will further strengthen Scancell's IP position around its proprietary ImmunoBody vaccine platform.

By MoneyWeek

published 9 March 2012

Software Radio Technology has said results for the year ended March 31st are expected to be below expectations, with revenue of around £6m and profit before tax of about £0.1m, after the firm was hit by order delays. Chief Executive Simon Tucker said: "Whilst the expected outcome for the financial year is significantly below what we had hoped and is therefore disappointing, we have made substantial progress in the execution of our product, customer and market development strategies."

Media firm Aeorema Communications has acquired Viral Film Maker for £85,500, paid partly in cash and the remainder with the issue of 200,000 new ordinary shares in the Aeorema at 23.25p each. For the year ended June 30th 2011, ST16 recorded profit before tax of around £23,000 (unaudited) on turnover of about £216,000. As at the end of the period, ST16 had net assets of approximately £2,000.